Lebanon MoPH Authorized Implantable Medical Devices Teardown

Middle East Market Access: Navigating Lebanon's Implantable Registry

For global regulatory affairs and market-access professionals targeting the Middle East and North Africa (MENA) region, the regulatory landscape is often characterized by a high degree of variation. While the Gulf Cooperation Council (GCC) member states have moved toward unified, comprehensive device registries—such as the Saudi Food and Drug Authority (SFDA) Medical Device Marketing Authorization (MDMA) system—other Levant nations maintain unique, country-specific pathways.

Among these, the Republic of Lebanon represents a meaningful and distinct market. Historically, Lebanon has been a regional hub for medical tourism and advanced clinical specialties, particularly in orthopedics, cardiology, and plastic surgery. However, the regulatory framework governing medical hardware in Lebanon operates on a model that is completely different from its GCC neighbors.

Under the jurisdiction of the Ministry of Public Health (MoPH), Lebanon regulates medical devices through a hybrid system established by MoPH Decree 455/1 (issued 16 April 2013, effective 1 July 2013). Unlike comprehensive registries that cover every device from Class I consumables to Class III active implants, Lebanon's formal registration system is restricted exclusively to implantable medical devices. Non-implantable devices enter the country under a simpler import-permit system managed by the Directorate General of Pharmaceutical Affairs (DGPA), without a requirement for full product registry listing.

For manufacturers evaluating this Levant market, understanding the structure of the MoPH List of Authorized Implantable Medical Devices is critical. In this teardown, we analyze the registry data to quantify manufacturer concentration, supplier/distributor franchises, risk class distributions, and the certification pathways required to enter this market. We also compare this framework with neighboring markets, referencing our previous analyses of the Saudi SFDA registered devices teardown, the UAE EDE supplier concentration, the Jordan JFDA registry analysis, and the Israel MoH register analysis.

Scenario Question:

We are an orthopedic/cardiac implant manufacturer evaluating Lebanon — which implantables are authorized, who dominates, and what does the MoPH implantable-only rule mean for market entry?

Direct Answer:

Under Decree 455/1, Lebanon's MoPH maintains a dedicated register of authorized implants (the List of Registered Implantable Medical Devices, managed within the Medical Device Registry System - MDRS).

Our analysis of the primary MoPH registry database (representing 2,678 active authorized implant records as of June 2026) reveals the following key structural details:

• The Implant Register Scale: The registry contains 2,678 authorized product lines representing 339 unique manufacturers globally, distributed through 174 in-country suppliers/distributors.
• Orthopedic and Cardiac Concentration: The register is heavily dominated by a small group of global orthopedic and cardiac giants. Smith & Nephew (96 records), DePuy/J&J (69), Medtronic (65), Zimmer (64), J&J Ethicon EPD (64), aap Implantate (60), Permedica (57), Arthrex (55), Evolutis (54), and Boston Scientific (43) lead the database, representing a combined 23.4% of all registrations.
• Overwhelmingly High-Risk Profile: Because the database is implantable-only, the risk profile is extremely high. 91.8% of all registered products fall into Class IIb (1,234 records, 46.1%), Class III (1,146 records, 42.8%), or Active Implantable Medical Devices (AIMD, 79 records, 2.9%). Class IIa, II (legacy), and Class I codes account for the remaining 8.2%.
• US and EU Conformity Alignment: Lebanon does not perform independent technical reviews of device safety and efficacy. Instead, it relies on reliance pathways. Conformity is established by submitting a Certificate for Foreign Government (CFG) from the US FDA, an EC Certificate under EU MDD/MDR, or a Free Sale Certificate (FSC) from a recognized GHTF founding member state.
• No Registration Fees: Crucially, unlike most Middle Eastern markets where registration fees run from $1,000 to $5,000 per device, Lebanon's MoPH does not charge registration fees for medical devices. However, foreign manufacturers must appoint a Local Authorized Representative (AR) and work through registered Lebanese distributors who hold physical import permits.

What does Lebanon's MoPH implantable-only regulatory regime require?

The most critical distinction of Lebanon's medical device framework is the division of regulatory pathways based on whether a device is implantable. Under Decree 455/1, an implantable medical device is defined in alignment with European Union standards: any device intended to be totally introduced into the human body or to replace an epithelial surface or the surface of the eye, by surgical intervention, and which is intended to remain in place after the procedure for at least 30 days.

The regulatory pathways split as follows:

                  [Medical Device for Lebanon Market]
                                   |
                   Is the device surgically implantable?
                     /                           \
                   YES                            NO
                   /                               \
                  v                                 v
   [MoPH Registration Pathway]             [DGPA Import Pathway]
  - Full dossier submission required       - No product registry listing
  - Must be listed in MDRS database        - Simpler import-permit basis
  - Local AR required                      - Obtained per-shipment
  - No MoPH registration fee               - Local distributor handles

1. The Implantable Registration Pathway (MDRS Listing)

For any device meeting the implantable definition, the manufacturer cannot import or commercialize the product until it has been formally evaluated and listed on the MoPH List of Authorized Implantable Medical Devices. The submission must be made by a licensed local distributor acting as the manufacturer's Local Authorized Representative (AR). The dossier must include:

• An active ISO 13485 quality system certificate for the manufacturing site.
• Premarket approval documentation from a recognized reference country (FDA 510(k)/PMA or CE Certificate).
• A Certificate for Foreign Government (CFG) or Free Sale Certificate (FSC).
• Detailed product catalog numbers, descriptions, and packaging labels.
• Clinical data summaries (for Class III and novel Class IIb devices).

2. The Non-Implantable Import Pathway

For non-implantable devices (such as surgical gloves, catheters, patient monitors, or external orthopedic braces), there is no requirement to list the product in the MoPH database. Instead, these devices enter the country via import licenses issued on a per-shipment basis by the Directorate General of Pharmaceutical Affairs (DGPA) under the MoPH. The local importer must submit the manufacturer's ISO 13485 certificate and a Free Sale Certificate to clear customs, but the process is significantly faster and does not involve a permanent registry listing.

Overall Register Metrics: Risk Class and Certification Pathways

When we analyze the 2,678 active authorized implant records in the MoPH registry, we find that the registry represents a highly specialized, high-risk subset of medical technology.

Risk Class Distribution

Because the register is restricted to implantable devices, the risk classification is heavily weighted toward the highest categories defined by the GHTF and EU MDR frameworks. The table below breaks down the registry by risk class:

Data Source: Lebanon MoPH Registry, June 2026.

Over 91.8% of the registry (2,459 records) consists of Class IIb, Class III, and AIMD products. This concentration of high-risk hardware is unique compared to general registries. For example, in our Oman MoH registered devices teardown, Class I and Class IIa consumables represent over 60% of the active database. The Lebanese registry is focused almost entirely on high-value surgical hardware.

Certification Pathways

Lebanon's reliance model accepts regulatory approvals from established markets. The certifications cited across the register are not mutually exclusive — most records carry more than one certificate, with notified-body numbers and expiry dates embedded in the free-text field — so the figures below describe how commonly each route appears, not an exclusive split:

1. CE Mark (EC-Full Quality Assurance): The dominant conformity pathway, appearing in the overwhelming majority of registrations. This reflects the historical influence of European medical technology in Lebanon, supported by bilateral cooperation programs like the French ANSM and Lebanese ESA initiative that originally designed Decree 455/1.
2. US FDA CFG (Certificate for Foreign Government): A major secondary route, particularly for US multinationals such as Medtronic, Boston Scientific, and Zimmer Biomet, allowing them to register their FDA-cleared or approved implants directly.
3. Free Sale Certification (FSC): Used by a substantial share of registrations, typically for implants manufactured in Canada, Japan, or Australia, referencing their home-country regulatory approvals.

Manufacturer Concentration: The Global Giants

A key metric for evaluating market dynamics is manufacturer concentration—measuring the extent to which a few large corporations control the registered product lines. In Lebanon, this concentration is high, driven by the orthopedic-heavy nature of the implant registry.

The table below ranks the top 10 manufacturers by the number of active authorized implant registrations they hold in Lebanon:

Data Source: Lebanon MoPH Registry, June 2026. Names reflect the raw registration listings.

Market Structure Implications:

• The Orthopedic Oligopoly: Five of the top ten manufacturers (Smith & Nephew, DePuy, Zimmer, Permedica, Evolutis) are dedicated orthopedic reconstruction and trauma firms. When we add Arthrex (sports medicine and soft-tissue anchors) and aap Implantate (trauma plating), seven of the ten leaders sit in the orthopedics and trauma space — together accounting for roughly 73% of top-10 registrations (455 of 627). For details on how these same firms manage post-market risks globally, see our FDA orthopedic joint replacement implant analysis.
• The Cardiovascular Anchor: Medtronic and Boston Scientific represent the cardiac pacing and interventional cardiology segments. Their registrations consist of high-value Class III and AIMD systems (pacemakers, leads, stents, and transcatheter valves) that represent a significant share of the clinical spend in Lebanese hospitals.
• The Suture Baseline: J&J Ethicon's position at #5 is driven by surgical sutures. Although sutures are classified as Class IIb or Class III implants depending on absorption characteristics, they are high-volume consumables used in every surgical discipline, requiring a broad assortment of registered product codes.

Approval Cohort Analysis: The Registry Timeline

When we analyze the date of approval (the date the MoPH formally authorized the implant), the data reveals a clear regulatory timeline:

• The 2018 Peak (1,029 records): The registry's largest single approval cohort dates to 2018 (38.4% of all active records). This peak represents the initial implementation phase of the electronic Medical Device Registry System (MDRS) under Decree 455/1. During this period, the MoPH cleared a massive backlog of legacy implants that had been entering the country under older, non-electronic import permits.
• The COVID-19 Slump (2020–2021): Registrations dropped to 87 in 2020 and 60 in 2021. This decline was caused by the combined impact of the COVID-19 pandemic and the severe economic crisis in Lebanon, which led to administrative delays at the MoPH and temporary supply constraints.
• The Recovery Phase (2024–2025): The registry has recovered, with 205 new registrations in 2024 and 209 in 2025. This shows that despite economic challenges, global manufacturers are continuing to register new implant models to support Lebanese surgical clinics.

The Local Representative and Supplier Landscape

In Lebanon, a foreign manufacturer cannot register products directly. Under MoPH regulations, you must appoint a licensed Lebanese distributor to act as your Local Authorized Representative (AR).

The registry contains 174 unique local suppliers/distributors holding implant franchises.

This distributor landscape is characterized by a "hub-and-spoke" model. While there are 174 active suppliers in the database, the top 15 distributors control over 50% of all registrations. These dominant distributors act as local regulatory departments for multiple smaller foreign manufacturers, managing the MoPH submissions, coordinate import approvals, and handle logistics.

Strategic Channel Considerations:

1. The Distributor Lock-In Risk: Similar to the dynamics we identified in the UAE EDE supplier concentration analysis, appointing a local distributor as your AR creates a regulatory relationship. If the commercial relationship fails, transferring the MoPH registration to a new distributor requires a formal "No Objection Certificate" (NOC) signed by the outgoing distributor. If the distributor refuses, the registration can remain locked, preventing imports.
2. No MoPH Registration Fees: The absence of government registration fees is a distinct advantage of the Lebanese market. In neighboring Jordan, the JFDA charges fees for every registry application. In Lebanon, the costs are entirely operational—limited to local representative service fees, document legalization, and translation. This makes entering Lebanon with a broad product catalog commercially viable, even for niche implant sizes.
3. Import Licensing Integration: The MoPH coordinates directly with the Lebanese Customs Administration. When an implant shipment arrives at Beirut Rafic Hariri International Airport, the customs officers cross-check the invoice catalog numbers against the active list of authorized implants in the MDRS database. Any mismatch or expired certification leads to immediate detention of the shipment.

Step-by-Step Registration Workflow for Local Suppliers

To successfully commercialize an implantable medical device in Lebanon, the foreign manufacturer and their local distributor must collaborate through a multi-stage approval workflow. Although the absence of MoPH user fees simplifies the financial planning, the administrative requirements are strict, particularly regarding document authentication.

The operational stages of the registration process are detailed below:

1. Document Legalization: The manufacturer gathers the ISO 13485 QMS certificate, the CE Certificate or FDA CFG, and the Free Sale Certificate. These must be legalized at the Lebanese Embassy or Consulate in the manufacturer's home country.
2. Translation and Dossier Preparation: The local distributor translates any non-English/non-French documents. The local partner compiles the MDRS dossier, detailing every catalog number, size variant, and raw material composition.
3. MDRS Portal Upload: The local distributor, acting as the AR, logs into the MoPH Medical Device Registry System (MDRS) and uploads the legalized certificates, product specifications, and labeling materials.
4. Technical Committee Review: The MoPH Technical Committee reviews the dossier. If deficiencies are found (e.g., certificate nearing expiry or missing catalog numbers), they issue a deficiency letter. The distributor has 30 days to respond.
5. MDRS Listing Activation: Upon successful review, the MoPH adds the device to the List of Authorized Implantable Medical Devices. The listing displays the manufacturer, local supplier, and approved catalog numbers.
6. Customs Clearance Integration: When a shipment arrives at Beirut Rafic Hariri International Airport, customs officers access the MDRS database to verify the catalog numbers on the shipping invoice. Matching shipments are cleared immediately.

Critical Legalization Requirements:

A common cause of registration delays is the failure to properly legalize reference country certificates. The MoPH will not accept standard photocopies or digital copies of an FDA CFG or a CE Certificate.

To satisfy the requirements:

• Chamber of Commerce: The certificates must first be notarized or authenticated by the relevant local authority or Chamber of Commerce in the manufacturer's country.
• Ministry of Foreign Affairs: The documents must then be stamped by the Ministry of Foreign Affairs (or equivalent, such as the Department of State in the United States).
• Lebanese Consulate: Finally, the Lebanese Embassy or Consulate in the manufacturer's country must stamp the physical document. This process must be completed before the dossier is submitted to the MoPH Technical Committee.

How Lebanon Compares to Neighboring MENA Markets

For market-entry planning, MedTech executives must compare Lebanon's regulatory framework with other MENA markets. The table below provides a side-by-side comparison:

Source: MedDeviceGuide Market Access Intelligence, 2026.

Operational Takeaways:

• Lebanon is Highly Focused: If you manufacture non-implantable devices, Lebanon is the easiest MENA market to enter, as it does not require formal product registration. However, if you manufacture implants, the regulatory requirements are just as strict as those in Saudi Arabia, though the lack of registration fees reduces the initial capital barrier.
• The Reliance Model is Efficient: Lebanon's reliance on FDA CFGs and CE Certificates means that if you have already cleared your device in the US or Europe, the technical dossier preparation is simple. The primary effort lies in identifying a reliable local distributor and structuring a secure AR agreement.

Frequently Asked Questions (FAQs)

Do non-implantable devices need MoPH registration in Lebanon, or only an import permit?

Non-implantable devices do not require formal registration in the MoPH database. They only require a per-shipment import permit issued by the Directorate General of Pharmaceutical Affairs (DGPA) under the MoPH. The local importer handles this permit by submitting the manufacturer's ISO 13485 certificate and home-country Free Sale Certificate at the time of importation.

Does a foreign implant manufacturer need a Local Authorized Representative in Lebanon?

Yes. Under Decree 455/1, foreign manufacturers must appoint a licensed local distributor to act as their Local Authorized Representative (AR). The AR must be a Lebanese entity licensed by the MoPH to import and distribute medical devices. The AR is responsible for submitting the registration dossier through the MDRS system and serves as the official point of contact for safety communications and recalls.

Are there government fees for MoPH medical-device registration in Lebanon?

No. The Lebanese Ministry of Public Health does not charge administrative fees for registering implantable medical devices or for issuing import permits. This is a significant policy difference from other Middle Eastern countries, where registration fees can be a major barrier to entry. The only costs associated with registration are the service fees charged by your local AR and the cost of preparing and legalizing documents.

Strategic Recommendations for MENA Access Managers

For medical device companies evaluating the Lebanese market, we recommend the following strategic steps:

• Draft Secure Authorized Representative Contracts: Because changing your local AR in Lebanon requires a No Objection Certificate from the current distributor, manufacturers should include clear termination clauses in their distribution agreements. These clauses should oblige the distributor to transfer the MoPH registrations immediately upon termination, without requiring additional compensation.
• Coordinate Registration with Product Launches: Although there are no registration fees, the MoPH review process takes 3 to 6 months. Implant manufacturers should initiate the registration process early, ensuring that the local AR submits the dossier as soon as the CE Mark or FDA clearance is obtained, preventing delays in clinical adoption.
• Audit Distributor Certification Portfolios: Since Lebanon relies on external certifications, any expiration of your CE Certificate or US FDA CFG will immediately invalidate your MoPH registration. Access managers should set up a tracking system to ensure their local distributors receive updated certificates before the old ones expire, preventing border hold-ups.

Sources

1. Lebanese Ministry of Public Health (MoPH): List of Registered Implantable Medical Devices at MoPH (MDRS Database)
2. Lebanese Ministry of Public Health (MoPH): Regulation of the Importation & Use of Medical Devices — Decree 455/1 (16 April 2013, effective 1 July 2013)
3. Syndicate of Hospitals in Lebanon: The Lebanese Regulatory System for Medical Devices (ANSM/ESA cooperation; origins of Decree 455/1)
4. RegDesk: Lebanon Medical Device Regulations (Implantable-only, No Fees, Import Permit)
5. IPC Global (MedicalRegistration.net): Medical Device Registration in Lebanon (MoPH classification, Local AR requirements)